Its combination with tamoxifen in the phase II PIKTAM trial in HR-positive, HER2-negative advanced breast cancer patients was terminated early due to its risk-benefit profile despite its promising efficacy in the PIK3CA-mutated group with a median PFS of 8.7 months, ORR of 40%, and DCR of 80% [109]. This evidence concerns the gene ERBB2 and breast carcinoma.